Edwards Lifesciences Stock: Beat & Raised, But Near 52-Week Lows — Why We Say BUY (EW)

Edwards Lifesciences Corporation (EW) Q2 2026 — Edwards Lifesciences (EW) reported Q2 2026 with a clean beat-and-raise: sales grew 13.6% to $1.74B (+12.5% constant currency) and adjusted EPS was $0.78, up ~16% YoY and above consensus. (GAAP EPS was $0.42, depressed by a one-time discrete tax hit from Pillar Two global-minimum-tax rules and a California R&D-credit change — the adjusted figure is the real earnings power.) The core TAVR aortic-valve franchise did $1.26B (+11.3%; +10.5% cc), Surgical was $284M (+6.5%), and the standout was TMTT (transcatheter mitral & tricuspid) at $195.9M, up 47.3% as the PASCAL and EVOQUE platforms scale. Gross margin was 77.5% (adj 77.6%) and adjusted operating margin 30.0%. The balance sheet is a fortress: ~$2.9B cash vs ~$0.6B debt (~$2.3B net cash), ~$1.5B buyback authorization, no dividend. Management RAISED full-year guidance: sales growth to 10-11% (from 9-11%), implying ~$6.6-6.9B in sales, TAVR growth to 8-9%, and TMTT to $760-780M, while reaffirming adjusted EPS of $2.95-3.05 (+17% at midpoint); Q3 guide is $1.63-1.71B sales and $0.71-0.77 EPS. Despite all that, the stock sits near 52-week lows around $83 (52-wk range ~$72-96). Our owner-earnings / DCF pegs fair value near $92 — roughly 11% above the price and a touch below the Street's bullish ~$100 average (32 buys / 16 holds). Our call: BUY, 4/5. Edwards Lifesciences is a rare thing — a best-in-class medical-device franchise that just beat earnings, raised full-year guidance the same day, and then watched its stock slip toward 52-week lows. Edwards is the world leader in structural heart: the replacement heart valves and repair clips doctors thread up through an artery instead of opening your chest. Q2 2026 sales grew ~14% to $1.74B, adjusted EPS beat at $0.78 (+16%), and the brand-new mitral & tricuspid business (TMTT) grew 47% to $196M — a new multibillion-dollar market Edwards is building almost from scratch. The core TAVR aortic franchise ($1.26B, +11%) is maturing but still dominant, and the balance sheet is a fortress with ~$2.3B net cash and an active buyback. The overhangs are real — TAVR's deceleration, a September CMS national-coverage decision, and a fair-not-cheap ~27x forward multiple that leaves only a modest margin of safety. But our owner-earnings / DCF lands fair value near $92 versus a ~$83 price, and Wall Street is even more bullish at ~$100 (32 buys / 16 holds). A high-quality compounder on sale after a boredom-driven pullback. Our call: BUY, 4/5 — scale in, not back up the truck. Not financial advice. THE CALL: BUY (4/5, A STRUCTURAL-HEART COMPOUNDER ON SALE — BEAT, RAISED, AND TRADING AT A DOUBLE-DIGIT DISCOUNT TO FAIR VALUE) — base-case value ~$92 vs ~$83 today. KEY METRICS: - Adjusted EPS $0.78 (+~16% YoY), beat consensus; GAAP EPS $0.42 (depressed by a discrete Pillar Two / California R&D-credit tax hit) - Revenue $1.74B (+13.6% YoY reported; +12.5% constant currency) - TAVR (aortic) sales $1.26B (+11.3%; +10.5% cc) — ~72% of revenue, SAPIEN platform #1 globally - TMTT (mitral/tricuspid) sales $195.9M (+47.3%; +44.8% cc) — PASCAL & EVOQUE scaling - Surgical sales $284M (+6.5%; +5.0% cc) on durable RESILIA tissue - Gross margin 77.5% (adj 77.6%); adjusted operating margin 30.0% (GAAP 29.5%) - SG&A $561M (32.2% of sales); R&D $279M (16.0% of sales) - Balance sheet: ~$2.9B cash, ~$0.6B debt (~$2.3B net cash); ~$1.5B buyback authorization; no dividend - RAISED FY26 sales growth guide to 10-11% (from 9-11%) -> ~$6.6-6.9B; TAVR growth 8-9%; TMTT $760-780M - Reaffirmed FY26 adjusted EPS $2.95-3.05 (+17% at midpoint); Q3 guide sales $1.63-1.71B, adj EPS $0.71-0.77 - Catalysts ahead: CMS TAVR national-coverage decision memo (September); PASCAL tricuspid U.S. approval & next-gen PASCAL Capture Clarity (Q4); PROGRESS & CLASP IITR data at TCT - Valuation: ~27x forward earnings; stock ~$83 near 52-week low (range ~$72-96); our DCF fair value ~$92; Street ~$100 avg What to watch: continued 40%+ growth in the TMTT mitral/tricuspid franchise, a smooth ramp of the next-generation PASCAL and SAPIEN M3 launches, and a favorable September CMS national-coverage decision would confirm the growth-engine thesis and push fair value above $92 toward the Street's ~$100; the risk to respect is TMTT adoption stalling, an aortic-valve price war, or an adverse CMS ruling — at a premium multiple on a maturing core, a growth stumble is what re-rates the stock, so watch the TMTT growth rate and the CMS memo every quarter Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.